Is ICU Medical (ICUI) overvalued or fairly valued?

MarketChacha shows ICU Medical's valuation in context — a trailing P/E of about 51.6, a forward P/E of about 17.1, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is ICU Medical's revenue?

ICU Medical reported revenue of $2.2B for FY2025, with net profit of $732,000, per official filings.

What is the share price of ICU Medical (ICUI)?

ICU Medical last traded at $167.58 (+0.8% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

ICU Medical

ICUI · NYSE · Healthcare · United States

Snapshot

TickerICUI

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees13,000

HeadquartersSan Clemente, United States

Websitewww.icumed.com

Filings tracked12

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Who owns it

Insiders1.8%
Institutions98.2%
Public & other0.0%

399 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.02%
Jupiter Topco LLC11.13%
Vanguard Portfolio Management LLC5.88%
Fuller & Thaler Asset Management Inc.5.19%
Vanguard Capital Management LLC4.49%
Dimensional Fund Advisors LP4.21%
State Street Corporation4.10%
Schroder Investment Management Group2.96%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 0.0% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-1.3% → 0.0%

Margin has expanded by about 1.3 points — the business is getting more profitable.

Return on equity0.0%

Latest ROE of 0.0% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $561.6M · EPS 2.23

Est. earnings growth +17.0%

Next fiscal year

Rev $2.3B · EPS 9.65

Est. earnings growth +10.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.2B

Net margin

0.0%

ROE

0.0%

Revenue CAGR (2y)

-0.6%

EPS (FY2025)

0.03

Net profit (FY2025)

$732,000

Ask MarketChacha about ICUI

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.2B	$732,000	0.03	0.0%	0.0%
FY2024	$2.4B	$-117.7M	-4.83	-4.9%	-6.0%
FY2023	$2.3B	$-29.7M	-1.23	-1.3%	-1.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$551.7M	$19.1M	0.76	3.5%
2026Q1	$530.2M	$30.1M	1.20	5.7%
2025Q3	$537.0M	$-3.4M	-0.14	-0.6%
2025Q2	$548.9M	$35.3M	1.43	6.4%
2025Q1	$604.7M	$-15.5M	-0.63	-2.6%
2024Q3	$589.1M	$-33.0M	-1.35	-5.6%
2024Q2	$596.5M	$-21.4M	-0.88	-3.6%
2024Q1	$566.7M	$-39.5M	-1.63	-7.0%
2023Q3	$553.3M	$7.2M	0.30	1.3%
2023Q2	$549.3M	$-9.9M	-0.41	-1.8%
2023Q1	$568.6M	$-9.8M	-0.41	-1.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/18/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change, Exhibits
SEC2/20/2026material
8-K — Results of operations, Exhibits
SEC2/19/2026material
10-K filing
SEC2/19/2026

2025

8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.